Randomized trial shows radium-223 improves overall survival in metastatic prostate cancer, indicating its potential benefit.
In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
No takes yet. Share an insight, caveat, or question.
Parker et al. (2013) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: